Publication
Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.
Tynisha S Rafael, Alberto Gil-Jimenez, Laura Elst, Hielke M de Vries, Iris M Seignette, Elise Bekers, Marta Lopez-Yurda, Dennis Peters, Marja Nieuwland, Erik Hooijberg, Annegien Broeks, Oscar R Brouwer, Eva E Schaake, Diether Lambrechts, Lodewyk F A Wessels, Daniel J Vis, Maarten Albersen, Tanja D de Gruijl, Michiel S van der Heijden
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy in advanced penile cancer. Here, we report mature overall survival (OS) and updated…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT03686332registry_reference1.00
Candidate 1
- cancerMalignant Penile Neoplasmdictionary0.60
Registered trialsNCT03686332
Curated evidence
Evidence citing this paper (0)
Data not yet available